Ads
related to: current treatment for multiple sclerosis- Need a Second Opinion?
Put Our Expertise to Work for You.
Get a Virtual Second Opinion Today.
- Virtual Second Opinions
Get Peace of Mind from Home.
Review Your Diagnosis & Treatment.
- Multiple Sclerosis
Download a Free MS Treatment Guide
Learn More About Multiple Sclerosis
- Progressive MS
Download Our Free Information Guide
Discover MS Symptoms & Treatment
- Need a Second Opinion?
Search results
Results from the WOW.Com Content Network
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
Multiple sclerosis (MS) is an autoimmune disease resulting in damage to the insulating covers of nerve cells in the brain and spinal cord. [3] As a demyelinating disease, MS disrupts the nervous system's ability to transmit signals, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems.
Research in multiple sclerosis may find new pathways to interact with the disease, improve function, curtail attacks, or limit the progression of the underlying disease. Many treatments already in clinical trials involve drugs that are used in other diseases or medications that have not been designed specifically for multiple sclerosis. There ...
Multiple sclerosis, a chronic disease, may take 40 years to run its course. In developing drugs to slow its progression, doctors have used brain scans to show lesions (Science Photo Library)
The appropriate pathway to put forward masitinib through the regulatory agencies, for the treatment of progressive forms of multiple sclerosis, is under study [34] evobrutinib is a selective oral Bruton's tyrosine kinase (BTK) inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo. [35] [36] In phase III. [37]
In February 2016, the US Food and Drug Administration (FDA) granted breakthrough therapy designation for primary progressive multiple sclerosis. [21] In March 2017, the FDA approved ocrelizumab for relapsing-remitting and primary-progressive multiple sclerosis. It is the first FDA-approved treatment for the primary progressive form.
Ads
related to: current treatment for multiple sclerosis